Identification
NameChlorpropamide
Accession NumberDB00672  (APRD00029)
TypeSmall Molecule
GroupsApproved
Description

Chlorpropamide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the sulfonylurea class of insulin secretagogues, which act by stimulating β cells of the pancreas to release insulin. Sulfonylureas increase both basal insulin secretion and meal-stimulated insulin release. Medications in this class differ in their dose, rate of absorption, duration of action, route of elimination and binding site on their target pancreatic β cell receptor. Sulfonylureas also increase peripheral glucose utilization, decrease hepatic gluconeogenesis and may increase the number and sensitivity of insulin receptors. Sulfonylureas are associated with weight gain, though less so than insulin. Due to their mechanism of action, sulfonylureas may cause hypoglycemia and require consistent food intake to decrease this risk. The risk of hypoglycemia is increased in elderly, debilitated and malnourished individuals. Chlorpropamide is not recommended for the treatment of NIDDM as it increases blood pressure and the risk of retinopathy (UKPDS-33). Up to 80% of the single oral dose of chlorpropramide is metabolized, likely in the liver; 80-90% of the dose is excreted in urine as unchanged drug and metabolites. Renal and hepatic dysfunction may increase the risk of hypoglycemia.

Structure
Thumb
Synonyms
1-(P-Chlorobenzenesulfonyl)-3-propylurea
1-(P-Chlorophenylsulfonyl)-3-propylurea
1-Propyl-3-(P-chlorobenzenesulfonyl)urea
4-chloro-N-((Propylamino)carbonyl)benzenesulfonamide
4-chloro-N-[(Propylamino)carbonyl]benzenesulfonamide
Chlorpropamid
Chlorpropamide
Chlorpropamidum
Clorpropamida
N-(4-Chlorophenylsulfonyl)-n'-propylurea
N-(P-Chlorobenzenesulfonyl)-n'-propylurea
N-Propyl-n'-(P-chlorobenzenesulfonyl)urea
N-Propyl-n'-P-chlorophenylsulfonylcarbamide
External IDs Hoechst 18810 / P 607 / U 9818
Product Ingredients Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Chlorpropamide 100 Tab USPTablet100 mgOralPro Doc Limitee1983-12-312009-07-23Canada
Chlorpropamide Tab 250mgTablet250 mgOralDuchesnay Inc.1978-12-312003-07-18Canada
Chlorpropamide Tab 250mgTablet250 mgOralPro Doc Limitee1969-12-312009-07-23Canada
Diabinese Tab 100mgTablet100 mgOralPfizer1958-12-312000-10-18Canada
Diabinese Tab 250mgTablet250 mgOralPfizer1958-12-312000-07-26Canada
Novo-propamide 250mgTablet250 mgOralNovopharm Limited1969-12-312010-09-10Canada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo Chlorpropamide Tab 100mgTablet100 mgOralApotex Corporation1977-12-31Not applicableCanada
Apo Chlorpropamide Tab 250mgTablet250 mgOralApotex Corporation1974-12-31Not applicableCanada
ChlorpropamideTablet100 mg/1OralMylan Pharmaceuticals1984-06-01Not applicableUs
ChlorpropamideTablet250 mg/1OralMylan Pharmaceuticals1984-06-01Not applicableUs
ChlorpropamideTablet250 mg/1OralPd Rx Pharmaceuticals, Inc.1984-06-01Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
AbemideKobayashi Kako
ChloronaseHoechst
DabinesePfizer
DiabeedolSriprasit Dispensary
DiabemideGuidotti
DiabezinPrince
DiabinesePfizer
DiabitexPlantex-Ikapharm
DibeconPharmasant
GlyceminSiam Bheasach
HypomideAspen Pharmacare
LitangenMing Ta
PropamideAtlantic
TraneOmega
Brand mixturesNot Available
Categories
UNIIWTM2C3IL2X
CAS number94-20-2
WeightAverage: 276.74
Monoisotopic: 276.033540689
Chemical FormulaC10H13ClN2O3S
InChI KeyRKWGIWYCVPQPMF-UHFFFAOYSA-N
InChI
InChI=1S/C10H13ClN2O3S/c1-2-7-12-10(14)13-17(15,16)9-5-3-8(11)4-6-9/h3-6H,2,7H2,1H3,(H2,12,13,14)
IUPAC Name
1-(4-chlorobenzenesulfonyl)-3-propylurea
SMILES
CCCNC(=O)NS(=O)(=O)C1=CC=C(Cl)C=C1
Pharmacology
Indication

For treatment of NIDDM in conjunction with diet and exercise.

Structured Indications
Pharmacodynamics

Chlorpropamide, a second-generation sulfonylurea antidiabetic agent, is used with diet to lower blood glucose levels in patients with diabetes mellitus type II. Chlorpropamide is twice as potent as the related second-generation agent glipizide.

Mechanism of action

Sulfonylureas such as chlorpropamide bind to ATP-sensitive potassium channels on the pancreatic cell surface, reducing potassium conductance and causing depolarization of the membrane. Depolarization stimulates calcium ion influx through voltage-sensitive calcium channels, raising intracellular concentrations of calcium ions, which induces the secretion, or exocytosis, of insulin.

TargetKindPharmacological actionActionsOrganismUniProt ID
ATP-binding cassette sub-family C member 8Proteinyes
inhibitor
HumanQ09428 details
Related Articles
Absorption

Readily absorbed from the GI tract. Peak plasma concentrations occur within 2-4 hours and the onset of action occurs within one hour. The maximal effect of chlorpropamide is seen 3-6 hours following oral administration.

Volume of distributionNot Available
Protein binding

Highly bound to plasma proteins.

Metabolism

Up to 80% of dose is metabolized likely through the liver to to 2-hydroxylchlorpropamide (2-OH CPA), p-chlorobenzenesulfonylurea (CBSU), 3-hydroxylchlorpropamide (3-OH CPA), and p-chlorobenzenesulfonamide (CBSA); CBSA may be produced by decomposition in urine. It is unknown whether chlorpropamide metabolites exert hypoglycemic effects.

SubstrateEnzymesProduct
Chlorpropamide
2-HydroxychlorpropamideDetails
Chlorpropamide
Not Available
3-HydroxychlorpropamideDetails
Chlorpropamide
Not Available
p-Chlorobenzene sulfonylureaDetails
p-Chlorobenzene sulfonylurea
Not Available
p-Chlorobenzene sulfonamideDetails
Route of elimination

80-90% of a single oral dose is excreted in the urine as unchaged drug and metabolites within 96 hours.

Half life

Approximately 36 hours with interindividual variation ranging from 25-60 hours. Duration of effect persists for at least 24 hours.

ClearanceNot Available
Toxicity

IPN-RAT LD50 580 mg/kg

Affected organisms
  • Humans and other mammals
PathwaysNot Available
Pharmacogenomic Effects/ADRs
Interacting Gene/EnzymeAllele nameGenotype(s)Defining Change(s)Type(s)DescriptionDetails
Glucose-6-phosphate 1-dehydrogenaseVilleurbanneNot Available1000_1002delACCADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseTorunNot Available1006A->GADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseSunderlandNot Available105_107delCATADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseIwatsukiNot Available1081G->AADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseSerresNot Available1082C->TADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseTondelaNot Available1084_1101delCTGAACGAGCGCAAGGCCADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseLoma LindaNot Available1089C->AADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseAachenNot Available1089C->GADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseTenriNot Available1096A->GADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseMontpellierNot Available1132G>AADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseCalvo MackennaNot Available1138A->GADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseRileyNot Available1139T->CADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseOlomoucNot Available1141T->CADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseTomahNot Available1153T->CADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseLynwoodNot Available1154G->TADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseMadridNot Available1155C->GADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseIowa, Walter Reed, SpringfieldNot Available1156A->GADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseBeverly Hills, Genova, Iwate, Niigata, YamaguchiNot Available1160G->AADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseHartfordNot Available1162A->GADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenasePrahaNot Available1166A->GADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseKrakowNot Available1175T>CADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseWisconsinNot Available1177C->GADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseNashville, Anaheim, PorticiNot Available1178G->AADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseAlhambraNot Available1180G->CADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseBariNot Available1187C->TADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenasePuerto LimonNot Available1192G->AADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseCovao do LoboNot Available1205C>AADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseClinicNot Available1215G->AADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseUtrechtNot Available1225C->TADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseSuwalkiNot Available1226C->GADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseRiversideNot Available1228G->TADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseJapan, ShinagawaNot Available1229G->AADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseKawasakiNot Available1229G->CADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseMunichNot Available1231A->GADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseGeorgiaNot Available1284C->AADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseSumareNot Available1292T->GADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseTelti/KobeNot Available1318C->TADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseSantiago de Cuba, MoriokaNot Available1339G->AADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseHarimaNot Available1358T->AADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseFiguera da FozNot Available1366G->CADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseAmiensNot Available1367A>TADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseBangkok NoiNot Available1376G->T, 1502T->GADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseFukayaNot Available1462G->AADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseCampinasNot Available1463G->TADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseBuenos AiresNot Available1465C>TADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseArakawaNot Available1466C->TADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseBrightonNot Available1488_1490delGAAADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseKozukataNot Available159G->CADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseAmsterdamNot Available180_182delTCTADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseNo nameNot Available202G->A, 376A->G, 1264C>GADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseSwanseaNot Available224T->CADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseUrayasuNot Available281_283delAGAADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseVancouverNot Available317C->G544C->T592C->TADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseMt SinaiNot Available376A->G, 1159C->TADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenasePlymouthNot Available488G->AADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseVolendamNot Available514C->TADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseShinshuNot Available527A->GADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseChikugoNot Available535A->TADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseTsukuiNot Available561_563delCTCADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenasePedoplis-CkaroNot Available573C>GADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseSantiagoNot Available593G->CADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseMinnesota, Marion, Gastonia, LeJeuneNot Available637G->TADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseCincinnatiNot Available637G->T, 1037A->TADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseHarilaouNot Available648T->GADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseNorth DallasNot Available683_685delACAADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseAsahikawaNot Available695G->AADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseDurhamNot Available713A->GADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseStonybrookNot Available724_729delGGCACTADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseWayneNot Available769C->GADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseAveiroNot Available806G->AADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseCleveland CorumNot Available820G->AADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseLilleNot Available821A>TADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseBangkokNot Available825G>CADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseSugaoNot Available826C->TADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseLa JollaNot Available832T->CADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseWexhamNot Available833C->TADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenasePiotrkowNot Available851T>CADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseWest VirginiaNot Available910G->TADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseOmiyaNot Available921G->CADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseNaraNot Available953_976delCCACCAAAGGGTACCTGGAC GACCADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseManhattanNot Available962G->AADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseRehevotNot Available964T->CADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseHoniaraNot Available99A->G / 1360C->TADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseTokyo, FukushimaNot Available1246G->AADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseChathamNot Available1003G->AADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseFushanNot Available1004C->AADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenasePartenopeNot Available1052G->TADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseIerapetraNot Available1057C->TADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseAnadiaNot Available1193A->GADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseAbenoNot Available1220A->CADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseSurabayaNot Available1291G->AADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenasePawneeNot Available1316G->CADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseS. AntiocoNot Available1342A->GADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseCassanoNot Available1347G->CADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseHermoupolisNot Available1347G->C / 1360C->TADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseUnion,Maewo, Chinese-2, KaloNot Available1360C->TADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseAndalusNot Available1361G->AADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseCosenzaNot Available1376G->CADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseCanton, Taiwan- Hakka, Gifu-like, Agrigento-likeNot Available1376G->TADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseFloresNot Available1387C->AADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseKaiping, Anant, Dhon, Sapporo-like, WoseraNot Available1388G->AADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseKamogawaNot Available169C->TADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseCostanzoNot Available179T>CADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseAmazoniaNot Available185C->AADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseSongklanagarindNot Available196T->AADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseHechiNot Available202G->A / 871G->AADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseNamouruNot Available208T->CADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseBao LocNot Available352T>CADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseCrispimNot Available375G->T, 379G->T383T->C384C>TADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseAcrokorinthosNot Available376A->G / 463C->GADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseSanta MariaNot Available376A->G / 542A->TADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseAnanindeuaNot Available376A->G / 871G->AADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseVanua LavaNot Available383T->CADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseValladolidNot Available406C->TADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseBelemNot Available409C->TADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseLiuzhouNot Available442G->AADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseShenzenNot Available473G>AADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseTaipei “Chinese- 3”Not Available493A->GADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseToledoNot Available496C>TADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseNaoneNot Available497G->AADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseNankangNot Available517T->CADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseMiaoliNot Available519C->GADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseMediterranean, Dallas, Panama‚ Sassari, Cagliari, BirminghamNot Available563C->TADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseCoimbra ShundeNot Available592C->TADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseNilgiriNot Available593G>AADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseRadlowoNot Available679C->TADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseRoubaixNot Available811G>CADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseHaikouNot Available835A->GADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseChinese-1Not Available835A->TADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseMizushimaNot Available848A>GADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseOsakaNot Available853C->TADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseViangchan, JammuNot Available871G->AADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseSeoulNot Available916G->AADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseLudhianaNot Available929G->AADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseFarroupilhaNot Available977C->AADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseChinese-5Not Available1024C->TADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseRignanoNot Available130G>AADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseOrissaNot Available131C->GADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseG6PDNiceNot Available1380G>CADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseKamiube, KeelungNot Available1387C->TADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseNeapolisNot Available1400C->GADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseAuresNot Available143T->CADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseSplitNot Available1442C->GADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseKambosNot Available148C->TADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenasePalestrinaNot Available170G>AADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseMetapontoNot Available172G->AADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseMusashinoNot Available185C->TADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseAsahiNot Available202G->AADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseA- (202), Ferrara INot Available202G->A / 376A->GADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseMurcia OristanoNot Available209A->GADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseUbe KonanNot Available241C->TADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseLagosantoNot Available242G->AADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseGuangzhouNot Available274C->TADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseHammersmithNot Available323T->AADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseSinnaiNot Available34G->TADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseA- (680)Not Available376A->G / 680G->TADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseA- (968), Betica,Selma, GuantanamoNot Available376A->G / 968T->CADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseSalerno PyrgosNot Available383T>GADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseQuing YanNot Available392G->TADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseLagesNot Available40G->AADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseIleshaNot Available466G->AADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseMahidolNot Available487G->AADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseMalagaNot Available542A->TADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseSibariNot Available634A->GADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseMexico CityNot Available680G->AADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseNanningNot Available703C->TADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseSeattle, Lodi, Modena, Ferrara II, Athens-likeNot Available844G->CADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseBajo MaumereNot Available844G->TADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseMontalbanoNot Available854G->AADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseKalyan-Kerala, Jamnaga, RohiniNot Available949G->AADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseGaoheNot Available95A->GADR InferredIncreased risk of hemolytic anemia. Details
Interactions
Drug Interactions
DrugInteractionDrug group
2,4-thiazolidinedioneThiazolidinedione may increase the hypoglycemic activities of Chlorpropamide.Investigational
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the hypoglycemic activities of Chlorpropamide.Experimental
AbirateroneThe metabolism of Chlorpropamide can be decreased when combined with Abiraterone.Approved
AcarboseAcarbose may increase the hypoglycemic activities of Chlorpropamide.Approved, Investigational
AcebutololThe serum concentration of Acebutolol can be increased when it is combined with Chlorpropamide.Approved
AcenocoumarolChlorpropamide may increase the anticoagulant activities of Acenocoumarol.Approved
AcetaminophenThe serum concentration of Acetaminophen can be increased when it is combined with Chlorpropamide.Approved
AcetohexamideAcetohexamide may increase the hypoglycemic activities of Chlorpropamide.Withdrawn
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be increased when it is combined with Chlorpropamide.Approved, Vet Approved
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Chlorpropamide.Approved
AICA ribonucleotideAicar may increase the hypoglycemic activities of Chlorpropamide.Experimental
AlbiglutideAlbiglutide may increase the hypoglycemic activities of Chlorpropamide.Approved
AldosteroneThe serum concentration of Aldosterone can be increased when it is combined with Chlorpropamide.Experimental
AlitretinoinThe serum concentration of Alitretinoin can be increased when it is combined with Chlorpropamide.Approved, Investigational
AllopurinolThe serum concentration of Chlorpropamide can be increased when it is combined with Allopurinol.Approved
AlogliptinAlogliptin may increase the hypoglycemic activities of Chlorpropamide.Approved
AlprenololAlprenolol may increase the hypoglycemic activities of Chlorpropamide.Approved, Withdrawn
AmbrisentanThe serum concentration of Ambrisentan can be increased when it is combined with Chlorpropamide.Approved, Investigational
Aminosalicylic AcidAminosalicylic Acid may increase the hypoglycemic activities of Chlorpropamide.Approved
AmiodaroneThe metabolism of Chlorpropamide can be decreased when combined with Amiodarone.Approved, Investigational
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with Chlorpropamide.Approved
Ammonium chlorideThe serum concentration of Chlorpropamide can be increased when it is combined with Ammonium chloride.Approved, Vet Approved
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Chlorpropamide.Approved
AprepitantThe metabolism of Chlorpropamide can be increased when combined with Aprepitant.Approved, Investigational
AripiprazoleThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Aripiprazole.Approved, Investigational
ArmodafinilThe metabolism of Chlorpropamide can be decreased when combined with Armodafinil.Approved, Investigational
ArotinololArotinolol may increase the hypoglycemic activities of Chlorpropamide.Approved
Arsenic trioxideThe serum concentration of Arsenic trioxide can be increased when it is combined with Chlorpropamide.Approved, Investigational
ArticaineThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Articaine.Approved
AsenapineThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Asenapine.Approved
AtazanavirThe serum concentration of Atazanavir can be increased when it is combined with Chlorpropamide.Approved, Investigational
AtenololThe serum concentration of Atenolol can be increased when it is combined with Chlorpropamide.Approved
AtorvastatinAtorvastatin may increase the hypoglycemic activities of Chlorpropamide.Approved
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Chlorpropamide.Approved, Investigational
BalaglitazoneBalaglitazone may increase the hypoglycemic activities of Chlorpropamide.Investigational
BalsalazideBalsalazide may increase the hypoglycemic activities of Chlorpropamide.Approved, Investigational
BefunololBefunolol may increase the hypoglycemic activities of Chlorpropamide.Experimental
BendroflumethiazideThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Bendroflumethiazide.Approved
BenmoxinBenmoxin may increase the hypoglycemic activities of Chlorpropamide.Withdrawn
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Chlorpropamide.Approved, Vet Approved
BetaxololBetaxolol may increase the hypoglycemic activities of Chlorpropamide.Approved
BevantololBevantolol may increase the hypoglycemic activities of Chlorpropamide.Approved
BezafibrateBezafibrate may increase the hypoglycemic activities of Chlorpropamide.Approved
BisoprololBisoprolol may increase the hypoglycemic activities of Chlorpropamide.Approved
BoceprevirThe serum concentration of Boceprevir can be increased when it is combined with Chlorpropamide.Withdrawn
BopindololBopindolol may increase the hypoglycemic activities of Chlorpropamide.Approved
BortezomibThe metabolism of Chlorpropamide can be decreased when combined with Bortezomib.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Chlorpropamide.Approved
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Chlorpropamide.Approved
BrexpiprazoleThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Brexpiprazole.Approved
BromocriptineThe serum concentration of Bromocriptine can be increased when it is combined with Chlorpropamide.Approved, Investigational
BucindololBucindolol may increase the hypoglycemic activities of Chlorpropamide.Investigational
BuforminBuformin may increase the hypoglycemic activities of Chlorpropamide.Withdrawn
BufuralolBufuralol may increase the hypoglycemic activities of Chlorpropamide.Experimental, Investigational
BumetanideThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Bumetanide.Approved
BupranololBupranolol may increase the hypoglycemic activities of Chlorpropamide.Approved
BuserelinThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Buserelin.Approved
CabazitaxelThe serum concentration of Cabazitaxel can be increased when it is combined with Chlorpropamide.Approved
CaffeineThe serum concentration of Caffeine can be increased when it is combined with Chlorpropamide.Approved
CamptothecinThe serum concentration of Camptothecin can be increased when it is combined with Chlorpropamide.Experimental
CanagliflozinCanagliflozin may increase the hypoglycemic activities of Chlorpropamide.Approved
CapecitabineThe metabolism of Chlorpropamide can be decreased when combined with Capecitabine.Approved, Investigational
CarbamazepineThe metabolism of Chlorpropamide can be increased when combined with Carbamazepine.Approved, Investigational
CarbocisteineThe risk or severity of adverse effects can be increased when Chlorpropamide is combined with Carbocisteine.Approved
CarfilzomibThe serum concentration of Carfilzomib can be increased when it is combined with Chlorpropamide.Approved
CaroxazoneCaroxazone may increase the hypoglycemic activities of Chlorpropamide.Withdrawn
CarteololCarteolol may increase the hypoglycemic activities of Chlorpropamide.Approved
CarvedilolCarvedilol may increase the hypoglycemic activities of Chlorpropamide.Approved, Investigational
CastanospermineCastanospermine may increase the hypoglycemic activities of Chlorpropamide.Experimental
CeliprololCeliprolol may increase the hypoglycemic activities of Chlorpropamide.Approved, Investigational
CeritinibThe serum concentration of Chlorpropamide can be increased when it is combined with Ceritinib.Approved
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Chlorpropamide.Withdrawn
ChloramphenicolThe metabolism of Chlorpropamide can be decreased when combined with Chloramphenicol.Approved, Vet Approved
ChlorothiazideThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Chlorothiazide.Approved, Vet Approved
ChlorpromazineThe serum concentration of Chlorpromazine can be increased when it is combined with Chlorpropamide.Approved, Vet Approved
ChlorthalidoneThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Chlorthalidone.Approved
CholecalciferolThe metabolism of Chlorpropamide can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CiglitazoneCiglitazone may increase the hypoglycemic activities of Chlorpropamide.Experimental
CimetidineThe serum concentration of Chlorpropamide can be increased when it is combined with Cimetidine.Approved
CinoxacinCinoxacin may increase the hypoglycemic activities of Chlorpropamide.Approved, Withdrawn
CiprofibrateCiprofibrate may increase the hypoglycemic activities of Chlorpropamide.Approved
CiprofloxacinThe serum concentration of Ciprofloxacin can be increased when it is combined with Chlorpropamide.Approved, Investigational
CisplatinThe serum concentration of Cisplatin can be increased when it is combined with Chlorpropamide.Approved
CitalopramThe serum concentration of Citalopram can be increased when it is combined with Chlorpropamide.Approved
ClarithromycinThe serum concentration of Clarithromycin can be increased when it is combined with Chlorpropamide.Approved
ClobazamThe serum concentration of Clobazam can be increased when it is combined with Chlorpropamide.Approved, Illicit
ClofibrateClofibrate may increase the hypoglycemic activities of Chlorpropamide.Approved
ClomifeneThe serum concentration of Clomifene can be increased when it is combined with Chlorpropamide.Approved, Investigational
ClonidineThe serum concentration of Clonidine can be increased when it is combined with Chlorpropamide.Approved
ClopidogrelThe serum concentration of Clopidogrel can be increased when it is combined with Chlorpropamide.Approved, Nutraceutical
ClotrimazoleThe metabolism of Chlorpropamide can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe serum concentration of Clozapine can be increased when it is combined with Chlorpropamide.Approved
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Chlorpropamide.Approved
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Chlorpropamide.Approved
Conjugated estrogensThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Chlorpropamide.Approved
CorticotropinThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Corticotropin.Approved, Vet Approved
Cortisone acetateThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Cortisone acetate.Approved
CrizotinibThe serum concentration of Crizotinib can be increased when it is combined with Chlorpropamide.Approved
CyclosporineThe serum concentration of Cyclosporine can be increased when it is combined with Chlorpropamide.Approved, Investigational, Vet Approved
Cyproterone acetateThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Cyproterone acetate.Approved, Investigational
Dabigatran etexilateThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Chlorpropamide.Approved
DabrafenibThe serum concentration of Chlorpropamide can be decreased when it is combined with Dabrafenib.Approved
DactinomycinThe serum concentration of Dactinomycin can be increased when it is combined with Chlorpropamide.Approved
DanazolThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Danazol.Approved
DapagliflozinThe serum concentration of Dapagliflozin can be increased when it is combined with Chlorpropamide.Approved
DapoxetineDapoxetine may increase the hypoglycemic activities of Chlorpropamide.Investigational
DarunavirThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Darunavir.Approved
DasatinibThe serum concentration of Dasatinib can be increased when it is combined with Chlorpropamide.Approved, Investigational
DaunorubicinThe serum concentration of Daunorubicin can be increased when it is combined with Chlorpropamide.Approved
DebrisoquinThe serum concentration of Debrisoquin can be increased when it is combined with Chlorpropamide.Approved
DelavirdineThe metabolism of Chlorpropamide can be decreased when combined with Delavirdine.Approved
DeoxyspergualinDeoxyspergualin may increase the hypoglycemic activities of Chlorpropamide.Investigational
dersalazinedersalazine may increase the hypoglycemic activities of Chlorpropamide.Investigational
DesogestrelThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Desogestrel.Approved
DesvenlafaxineDesvenlafaxine may increase the hypoglycemic activities of Chlorpropamide.Approved
DexamethasoneThe serum concentration of Dexamethasone can be increased when it is combined with Chlorpropamide.Approved, Investigational, Vet Approved
DiazepamThe serum concentration of Diazepam can be increased when it is combined with Chlorpropamide.Approved, Illicit, Vet Approved
DiazoxideThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Diazoxide.Approved
DicoumarolChlorpropamide may increase the anticoagulant activities of Dicoumarol.Approved
DienogestThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Dienogest.Approved
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be increased when it is combined with Chlorpropamide.Approved
DiflunisalDiflunisal may increase the hypoglycemic activities of Chlorpropamide.Approved
DigitoxinThe serum concentration of Digitoxin can be increased when it is combined with Chlorpropamide.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Chlorpropamide.Approved
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be increased when it is combined with Chlorpropamide.Illicit
DiltiazemThe serum concentration of Diltiazem can be increased when it is combined with Chlorpropamide.Approved
DipyridamoleThe serum concentration of Dipyridamole can be increased when it is combined with Chlorpropamide.Approved
DisopyramideDisopyramide may increase the hypoglycemic activities of Chlorpropamide.Approved
DocetaxelThe serum concentration of Docetaxel can be increased when it is combined with Chlorpropamide.Approved, Investigational
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Chlorpropamide.Approved, Investigational, Vet Approved
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Chlorpropamide.Approved, Investigational
DrospirenoneThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Drospirenone.Approved
DulaglutideDulaglutide may increase the hypoglycemic activities of Chlorpropamide.Approved
DuloxetineDuloxetine may increase the hypoglycemic activities of Chlorpropamide.Approved
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Chlorpropamide.Approved
EfavirenzThe metabolism of Chlorpropamide can be decreased when combined with Efavirenz.Approved, Investigational
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Chlorpropamide.Approved, Investigational
EmpagliflozinEmpagliflozin may increase the hypoglycemic activities of Chlorpropamide.Approved
EnoxacinEnoxacin may increase the hypoglycemic activities of Chlorpropamide.Approved
EpinastineThe serum concentration of Epinastine can be increased when it is combined with Chlorpropamide.Approved, Investigational
EpinephrineThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Epinephrine.Approved, Vet Approved
ErlotinibThe serum concentration of Erlotinib can be increased when it is combined with Chlorpropamide.Approved, Investigational
ErythromycinThe serum concentration of Erythromycin can be increased when it is combined with Chlorpropamide.Approved, Vet Approved
EscitalopramEscitalopram may increase the hypoglycemic activities of Chlorpropamide.Approved, Investigational
Eslicarbazepine acetateThe metabolism of Chlorpropamide can be decreased when combined with Eslicarbazepine acetate.Approved
EsmololEsmolol may increase the hypoglycemic activities of Chlorpropamide.Approved
EsomeprazoleThe metabolism of Chlorpropamide can be decreased when combined with Esomeprazole.Approved, Investigational
EstradiolThe serum concentration of Estradiol can be increased when it is combined with Chlorpropamide.Approved, Investigational, Vet Approved
EstriolThe serum concentration of Estriol can be increased when it is combined with Chlorpropamide.Approved, Vet Approved
EstroneThe serum concentration of Estrone can be increased when it is combined with Chlorpropamide.Approved
Estrone sulfateThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Estrone sulfate.Approved
Etacrynic acidThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Etacrynic acid.Approved
EthanolThe risk or severity of adverse effects can be increased when Chlorpropamide is combined with Ethanol.Approved
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Chlorpropamide.Approved
Ethyl biscoumacetateChlorpropamide may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Ethynodiol diacetateThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Ethynodiol diacetate.Approved
EtofibrateEtofibrate may increase the hypoglycemic activities of Chlorpropamide.Approved
EtonogestrelThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Etonogestrel.Approved, Investigational
EtoperidoneEtoperidone may increase the hypoglycemic activities of Chlorpropamide.Approved
EtoposideThe serum concentration of Etoposide can be increased when it is combined with Chlorpropamide.Approved
EtravirineThe metabolism of Chlorpropamide can be decreased when combined with Etravirine.Approved
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Chlorpropamide.Approved
ExenatideExenatide may increase the hypoglycemic activities of Chlorpropamide.Approved, Investigational
EzetimibeThe serum concentration of Ezetimibe can be increased when it is combined with Chlorpropamide.Approved
FenofibrateFenofibrate may increase the hypoglycemic activities of Chlorpropamide.Approved
FesoterodineThe serum concentration of Fesoterodine can be increased when it is combined with Chlorpropamide.Approved
FexofenadineThe serum concentration of Fexofenadine can be increased when it is combined with Chlorpropamide.Approved
FidaxomicinThe serum concentration of Fidaxomicin can be increased when it is combined with Chlorpropamide.Approved
FleroxacinFleroxacin may increase the hypoglycemic activities of Chlorpropamide.Approved
FloxuridineThe metabolism of Chlorpropamide can be decreased when combined with Floxuridine.Approved
FluconazoleThe serum concentration of Chlorpropamide can be increased when it is combined with Fluconazole.Approved
FludrocortisoneThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Fludrocortisone.Approved
FluindioneChlorpropamide may increase the anticoagulant activities of Fluindione.Investigational
FlumequineFlumequine may increase the hypoglycemic activities of Chlorpropamide.Withdrawn
FluorouracilThe metabolism of Chlorpropamide can be decreased when combined with Fluorouracil.Approved
FluoxetineThe metabolism of Chlorpropamide can be decreased when combined with Fluoxetine.Approved, Vet Approved
FluoxymesteroneFluoxymesterone may increase the hypoglycemic activities of Chlorpropamide.Approved, Illicit
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Chlorpropamide.Approved
FluvastatinThe metabolism of Chlorpropamide can be decreased when combined with Fluvastatin.Approved
FluvoxamineThe metabolism of Chlorpropamide can be decreased when combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Fosamprenavir.Approved
FosphenytoinThe metabolism of Chlorpropamide can be increased when combined with Fosphenytoin.Approved
FurazolidoneFurazolidone may increase the hypoglycemic activities of Chlorpropamide.Approved, Vet Approved
FurosemideThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Furosemide.Approved, Vet Approved
GarenoxacinGarenoxacin may increase the hypoglycemic activities of Chlorpropamide.Investigational
GatifloxacinGatifloxacin may increase the hypoglycemic activities of Chlorpropamide.Approved, Investigational
GefitinibThe serum concentration of Gefitinib can be increased when it is combined with Chlorpropamide.Approved, Investigational
GemcitabineThe serum concentration of Gemcitabine can be increased when it is combined with Chlorpropamide.Approved
GemfibrozilThe metabolism of Chlorpropamide can be decreased when combined with Gemfibrozil.Approved
GemifloxacinGemifloxacin may increase the hypoglycemic activities of Chlorpropamide.Approved, Investigational
GlibornurideGlibornuride may increase the hypoglycemic activities of Chlorpropamide.Withdrawn
GliclazideChlorpropamide may increase the hypoglycemic activities of Gliclazide.Approved
GlimepirideGlimepiride may increase the hypoglycemic activities of Chlorpropamide.Approved
GlipizideChlorpropamide may increase the hypoglycemic activities of Glipizide.Approved
GliquidoneGliquidone may increase the hypoglycemic activities of Chlorpropamide.Approved
GlyburideChlorpropamide may increase the hypoglycemic activities of Glyburide.Approved
GoserelinThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Goserelin.Approved
GrazoprevirThe serum concentration of Grazoprevir can be increased when it is combined with Chlorpropamide.Approved
GrepafloxacinThe serum concentration of Grepafloxacin can be increased when it is combined with Chlorpropamide.Withdrawn
GusperimusGusperimus may increase the hypoglycemic activities of Chlorpropamide.Investigational
HaloperidolThe serum concentration of Haloperidol can be increased when it is combined with Chlorpropamide.Approved
HistrelinThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Histrelin.Approved
HydracarbazineHydracarbazine may increase the hypoglycemic activities of Chlorpropamide.Experimental
HydrochlorothiazideThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Hydrochlorothiazide.Approved, Vet Approved
HydrocortisoneThe serum concentration of Hydrocortisone can be increased when it is combined with Chlorpropamide.Approved, Vet Approved
HydroflumethiazideThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Hydroflumethiazide.Approved
Hydroxyprogesterone caproateThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Hydroxyprogesterone caproate.Approved
IbuprofenThe serum concentration of Ibuprofen can be increased when it is combined with Chlorpropamide.Approved
IdelalisibThe serum concentration of Idelalisib can be increased when it is combined with Chlorpropamide.Approved
IloperidoneThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Iloperidone.Approved
ImatinibThe serum concentration of Imatinib can be increased when it is combined with Chlorpropamide.Approved
ImipramineThe serum concentration of Imipramine can be increased when it is combined with Chlorpropamide.Approved
IndacaterolThe serum concentration of Indacaterol can be increased when it is combined with Chlorpropamide.Approved
IndalpineIndalpine may increase the hypoglycemic activities of Chlorpropamide.Investigational, Withdrawn
IndapamideThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Indapamide.Approved
IndenololIndenolol may increase the hypoglycemic activities of Chlorpropamide.Withdrawn
IndinavirThe serum concentration of Indinavir can be increased when it is combined with Chlorpropamide.Approved
IndomethacinThe serum concentration of Indomethacin can be increased when it is combined with Chlorpropamide.Approved, Investigational
Insulin AspartChlorpropamide may increase the hypoglycemic activities of Insulin Aspart.Approved
Insulin DetemirChlorpropamide may increase the hypoglycemic activities of Insulin Detemir.Approved
Insulin GlargineInsulin Glargine may increase the hypoglycemic activities of Chlorpropamide.Approved
Insulin GlulisineChlorpropamide may increase the hypoglycemic activities of Insulin Glulisine.Approved
Insulin HumanInsulin Human may increase the hypoglycemic activities of Chlorpropamide.Approved, Investigational
Insulin LisproInsulin Lispro may increase the hypoglycemic activities of Chlorpropamide.Approved
Insulin PorkInsulin Pork may increase the hypoglycemic activities of Chlorpropamide.Approved
IproclozideIproclozide may increase the hypoglycemic activities of Chlorpropamide.Withdrawn
IproniazidIproniazid may increase the hypoglycemic activities of Chlorpropamide.Withdrawn
IrbesartanThe metabolism of Chlorpropamide can be decreased when combined with Irbesartan.Approved, Investigational
IrinotecanThe serum concentration of Irinotecan can be increased when it is combined with Chlorpropamide.Approved, Investigational
IsocarboxazidIsocarboxazid may increase the hypoglycemic activities of Chlorpropamide.Approved
IsoniazidThe metabolism of Chlorpropamide can be decreased when combined with Isoniazid.Approved
IvermectinThe serum concentration of Ivermectin can be increased when it is combined with Chlorpropamide.Approved, Vet Approved
KetazolamThe serum concentration of Ketazolam can be increased when it is combined with Chlorpropamide.Approved
KetoconazoleThe serum concentration of Ketoconazole can be increased when it is combined with Chlorpropamide.Approved, Investigational
LabetalolLabetalol may increase the hypoglycemic activities of Chlorpropamide.Approved
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Chlorpropamide.Approved, Investigational
LamotrigineThe serum concentration of Lamotrigine can be increased when it is combined with Chlorpropamide.Approved, Investigational
LandiololAop200704 may increase the hypoglycemic activities of Chlorpropamide.Investigational
LanreotideChlorpropamide may increase the hypoglycemic activities of Lanreotide.Approved
LansoprazoleThe serum concentration of Lansoprazole can be increased when it is combined with Chlorpropamide.Approved, Investigational
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Chlorpropamide.Approved
LeflunomideThe metabolism of Chlorpropamide can be decreased when combined with Leflunomide.Approved, Investigational
LenalidomideThe serum concentration of Lenalidomide can be increased when it is combined with Chlorpropamide.Approved
LenvatinibThe serum concentration of Lenvatinib can be increased when it is combined with Chlorpropamide.Approved
LeuprolideThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Leuprolide.Approved, Investigational
LevetiracetamThe serum concentration of Levetiracetam can be increased when it is combined with Chlorpropamide.Approved, Investigational
LevobunololLevobunolol may increase the hypoglycemic activities of Chlorpropamide.Approved
LevofloxacinThe serum concentration of Levofloxacin can be increased when it is combined with Chlorpropamide.Approved, Investigational
LevomilnacipranThe serum concentration of Levomilnacipran can be increased when it is combined with Chlorpropamide.Approved
LevonorgestrelThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Levonorgestrel.Approved, Investigational
LinagliptinLinagliptin may increase the hypoglycemic activities of Chlorpropamide.Approved
Lipoic AcidLipoic Acid may increase the hypoglycemic activities of Chlorpropamide.Approved, Nutraceutical
LiraglutideLiraglutide may increase the hypoglycemic activities of Chlorpropamide.Approved
LomefloxacinLomefloxacin may increase the hypoglycemic activities of Chlorpropamide.Approved
LoperamideThe serum concentration of Loperamide can be increased when it is combined with Chlorpropamide.Approved
LopinavirThe metabolism of Chlorpropamide can be increased when combined with Lopinavir.Approved
LosartanThe serum concentration of Losartan can be increased when it is combined with Chlorpropamide.Approved
LovastatinThe metabolism of Chlorpropamide can be decreased when combined with Lovastatin.Approved, Investigational
LuliconazoleThe serum concentration of Chlorpropamide can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Chlorpropamide can be decreased when it is combined with Lumacaftor.Approved
LurasidoneThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Lurasidone.Approved
MannitolThe serum concentration of Mannitol can be increased when it is combined with Chlorpropamide.Approved, Investigational
MebanazineMebanazine may increase the hypoglycemic activities of Chlorpropamide.Withdrawn
MecaserminChlorpropamide may increase the hypoglycemic activities of Mecasermin.Approved, Investigational
Medroxyprogesterone acetateThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Medroxyprogesterone acetate.Approved, Investigational
Megestrol acetateThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Megestrol acetate.Approved, Vet Approved
MesalazineMesalazine may increase the hypoglycemic activities of Chlorpropamide.Approved
MestranolThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Mestranol.Approved
MetforminMetformin may increase the hypoglycemic activities of Chlorpropamide.Approved
MethenamineThe serum concentration of Chlorpropamide can be increased when it is combined with Hexamethylenetetramine.Approved, Vet Approved
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Chlorpropamide.Approved
MethotrimeprazineThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Methotrimeprazine.Approved
MethyclothiazideThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Methyclothiazide.Approved
Methylene blueMethylene blue may increase the hypoglycemic activities of Chlorpropamide.Investigational
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Chlorpropamide.Approved, Vet Approved
MethyltestosteroneMethyltestosterone may increase the hypoglycemic activities of Chlorpropamide.Approved
MetipranololMetipranolol may increase the hypoglycemic activities of Chlorpropamide.Approved
MetolazoneThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Metolazone.Approved
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Chlorpropamide.Approved, Investigational
MetreleptinMetreleptin may increase the hypoglycemic activities of Chlorpropamide.Approved
MiconazoleMiconazole may increase the hypoglycemic activities of Chlorpropamide.Approved, Investigational, Vet Approved
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Chlorpropamide.Approved, Illicit
MifepristoneThe serum concentration of Chlorpropamide can be increased when it is combined with Mifepristone.Approved, Investigational
MiglitolMiglitol may increase the hypoglycemic activities of Chlorpropamide.Approved
MiglustatMiglustat may increase the hypoglycemic activities of Chlorpropamide.Approved
MilnacipranMilnacipran may increase the hypoglycemic activities of Chlorpropamide.Approved
MinaprineMinaprine may increase the hypoglycemic activities of Chlorpropamide.Approved
MirabegronThe serum concentration of Mirabegron can be increased when it is combined with Chlorpropamide.Approved
MitiglinideMitiglinide may increase the hypoglycemic activities of Chlorpropamide.Approved, Investigational
MitoxantroneThe serum concentration of Mitoxantrone can be increased when it is combined with Chlorpropamide.Approved, Investigational
MoclobemideMoclobemide may increase the hypoglycemic activities of Chlorpropamide.Approved
ModafinilThe metabolism of Chlorpropamide can be decreased when combined with Modafinil.Approved, Investigational
MorphineThe serum concentration of Morphine can be increased when it is combined with Chlorpropamide.Approved, Investigational
MoxifloxacinMoxifloxacin may increase the hypoglycemic activities of Chlorpropamide.Approved, Investigational
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Chlorpropamide.Approved, Investigational
NadololThe serum concentration of Nadolol can be increased when it is combined with Chlorpropamide.Approved
Nalidixic AcidNalidixic Acid may increase the hypoglycemic activities of Chlorpropamide.Approved
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Chlorpropamide.Approved
NaloxoneThe serum concentration of Naloxone can be increased when it is combined with Chlorpropamide.Approved, Vet Approved
NateglinideChlorpropamide may increase the hypoglycemic activities of Nateglinide.Approved, Investigational
NefazodoneNefazodone may increase the hypoglycemic activities of Chlorpropamide.Approved, Withdrawn
NelfinavirThe serum concentration of Nelfinavir can be increased when it is combined with Chlorpropamide.Approved
NemonoxacinNemonoxacin may increase the hypoglycemic activities of Chlorpropamide.Investigational
NiacinThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Niacin.Approved, Investigational, Nutraceutical
NialamideNialamide may increase the hypoglycemic activities of Chlorpropamide.Withdrawn
NicardipineThe metabolism of Chlorpropamide can be decreased when combined with Nicardipine.Approved
NifedipineThe serum concentration of Nifedipine can be increased when it is combined with Chlorpropamide.Approved
NilotinibThe serum concentration of Nilotinib can be increased when it is combined with Chlorpropamide.Approved, Investigational
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Chlorpropamide.Approved
NitroaspirinNitroaspirin may increase the hypoglycemic activities of Chlorpropamide.Investigational
NizatidineThe serum concentration of Nizatidine can be increased when it is combined with Chlorpropamide.Approved
NorethisteroneThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Norethisterone.Approved
NorfloxacinNorfloxacin may increase the hypoglycemic activities of Chlorpropamide.Approved
NorgestimateThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Norgestimate.Approved
OctamoxinOctamoxin may increase the hypoglycemic activities of Chlorpropamide.Withdrawn
OctreotideOctreotide may increase the hypoglycemic activities of Chlorpropamide.Approved, Investigational
OfloxacinOfloxacin may increase the hypoglycemic activities of Chlorpropamide.Approved
OlanzapineThe serum concentration of Olanzapine can be increased when it is combined with Chlorpropamide.Approved, Investigational
OlsalazineOlsalazine may increase the hypoglycemic activities of Chlorpropamide.Approved
OmbitasvirThe serum concentration of Ombitasvir can be increased when it is combined with Chlorpropamide.Approved
OmeprazoleThe metabolism of Chlorpropamide can be decreased when combined with Omeprazole.Approved, Investigational, Vet Approved
OsimertinibThe serum concentration of Osimertinib can be increased when it is combined with Chlorpropamide.Approved
OxandroloneOxandrolone may increase the hypoglycemic activities of Chlorpropamide.Approved, Investigational
OxprenololOxprenolol may increase the hypoglycemic activities of Chlorpropamide.Approved
OxymetholoneOxymetholone may increase the hypoglycemic activities of Chlorpropamide.Approved, Illicit
PaclitaxelThe serum concentration of Paclitaxel can be increased when it is combined with Chlorpropamide.Approved, Vet Approved
PaliperidoneThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Paliperidone.Approved
PanobinostatThe serum concentration of Panobinostat can be increased when it is combined with Chlorpropamide.Approved, Investigational
PantoprazoleThe metabolism of Chlorpropamide can be decreased when combined with Pantoprazole.Approved
PargylinePargyline may increase the hypoglycemic activities of Chlorpropamide.Approved
ParoxetineParoxetine may increase the hypoglycemic activities of Chlorpropamide.Approved, Investigational
PasireotideChlorpropamide may increase the hypoglycemic activities of Pasireotide.Approved
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Chlorpropamide.Approved
PazufloxacinPazufloxacin may increase the hypoglycemic activities of Chlorpropamide.Investigational
PefloxacinPefloxacin may increase the hypoglycemic activities of Chlorpropamide.Approved
PegvisomantPegvisomant may increase the hypoglycemic activities of Chlorpropamide.Approved
PenbutololPenbutolol may increase the hypoglycemic activities of Chlorpropamide.Approved, Investigational
PentamidineChlorpropamide may increase the hypoglycemic activities of Pentamidine.Approved
PhenelzinePhenelzine may increase the hypoglycemic activities of Chlorpropamide.Approved
PhenforminPhenformin may increase the hypoglycemic activities of Chlorpropamide.Approved, Withdrawn
PhenindioneChlorpropamide may increase the anticoagulant activities of Phenindione.Approved
PheniprazinePheniprazine may increase the hypoglycemic activities of Chlorpropamide.Withdrawn
PhenobarbitalThe metabolism of Chlorpropamide can be increased when combined with Phenobarbital.Approved
PhenoxypropazinePhenoxypropazine may increase the hypoglycemic activities of Chlorpropamide.Withdrawn
PhenprocoumonChlorpropamide may increase the anticoagulant activities of Phenprocoumon.Approved
PhenytoinThe metabolism of Chlorpropamide can be increased when combined with Phenytoin.Approved, Vet Approved
PindololPindolol may increase the hypoglycemic activities of Chlorpropamide.Approved
PioglitazonePioglitazone may increase the hypoglycemic activities of Chlorpropamide.Approved, Investigational
PiperazineThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Piperazine.Approved, Vet Approved
PipotiazineThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Pipotiazine.Approved
PirlindolePirlindole may increase the hypoglycemic activities of Chlorpropamide.Approved
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Chlorpropamide.Approved
PivhydrazinePivhydrazine may increase the hypoglycemic activities of Chlorpropamide.Withdrawn
PolythiazideThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Polythiazide.Approved
PomalidomideThe serum concentration of Pomalidomide can be increased when it is combined with Chlorpropamide.Approved
PonatinibThe serum concentration of Ponatinib can be increased when it is combined with Chlorpropamide.Approved
PractololPractolol may increase the hypoglycemic activities of Chlorpropamide.Approved
PramlintidePramlintide may increase the hypoglycemic activities of Chlorpropamide.Approved, Investigational
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Chlorpropamide.Approved
PrazosinThe serum concentration of Prazosin can be increased when it is combined with Chlorpropamide.Approved
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Chlorpropamide.Approved, Vet Approved
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Chlorpropamide.Approved, Vet Approved
PrimidoneThe metabolism of Chlorpropamide can be increased when combined with Primidone.Approved, Vet Approved
ProbenecidThe protein binding of Chlorpropamide can be decreased when combined with Probenecid.Approved
ProgesteroneThe serum concentration of Progesterone can be increased when it is combined with Chlorpropamide.Approved, Vet Approved
PropranololThe serum concentration of Propranolol can be increased when it is combined with Chlorpropamide.Approved, Investigational
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Chlorpropamide.Approved
PrulifloxacinPrulifloxacin may increase the hypoglycemic activities of Chlorpropamide.Investigational
PyrimethamineThe metabolism of Chlorpropamide can be decreased when combined with Pyrimethamine.Approved, Vet Approved
QuetiapineThe serum concentration of Quetiapine can be increased when it is combined with Chlorpropamide.Approved
QuinethazoneThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Quinethazone.Approved
QuinidineThe serum concentration of Quinidine can be increased when it is combined with Chlorpropamide.Approved
QuinineQuinine may increase the hypoglycemic activities of Chlorpropamide.Approved
RanitidineThe serum concentration of Chlorpropamide can be increased when it is combined with Ranitidine.Approved
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Chlorpropamide.Approved, Investigational
RasagilineRasagiline may increase the hypoglycemic activities of Chlorpropamide.Approved
RepaglinideChlorpropamide may increase the hypoglycemic activities of Repaglinide.Approved, Investigational
ReserpineThe serum concentration of Reserpine can be increased when it is combined with Chlorpropamide.Approved
RifampicinThe serum concentration of Chlorpropamide can be decreased when it is combined with Rifampicin.Approved
RifapentineThe metabolism of Chlorpropamide can be increased when combined with Rifapentine.Approved
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Chlorpropamide.Approved, Investigational
RisperidoneThe serum concentration of Risperidone can be increased when it is combined with Chlorpropamide.Approved, Investigational
RitonavirThe serum concentration of Ritonavir can be increased when it is combined with Chlorpropamide.Approved, Investigational
RivaroxabanThe serum concentration of Rivaroxaban can be increased when it is combined with Chlorpropamide.Approved
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Chlorpropamide.Approved, Investigational
RosiglitazoneRosiglitazone may increase the hypoglycemic activities of Chlorpropamide.Approved, Investigational
RosoxacinRosoxacin may increase the hypoglycemic activities of Chlorpropamide.Approved
SafrazineSafrazine may increase the hypoglycemic activities of Chlorpropamide.Withdrawn
Salicylic acidThe serum concentration of Salicylic acid can be increased when it is combined with Chlorpropamide.Approved, Vet Approved
SaquinavirThe serum concentration of Saquinavir can be increased when it is combined with Chlorpropamide.Approved, Investigational
SaxagliptinSaxagliptin may increase the hypoglycemic activities of Chlorpropamide.Approved
SecobarbitalThe metabolism of Chlorpropamide can be increased when combined with Secobarbital.Approved, Vet Approved
SelegilineSelegiline may increase the hypoglycemic activities of Chlorpropamide.Approved, Investigational, Vet Approved
SelexipagThe serum concentration of Selexipag can be increased when it is combined with Chlorpropamide.Approved
SertralineThe metabolism of Chlorpropamide can be decreased when combined with Sertraline.Approved
SildenafilThe metabolism of Chlorpropamide can be decreased when combined with Sildenafil.Approved, Investigational
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Chlorpropamide.Approved
SimeprevirThe serum concentration of Simeprevir can be increased when it is combined with Chlorpropamide.Approved
SirolimusThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Sirolimus.Approved, Investigational
SitagliptinSitagliptin may increase the hypoglycemic activities of Chlorpropamide.Approved, Investigational
SofosbuvirThe serum concentration of Sofosbuvir can be increased when it is combined with Chlorpropamide.Approved
SorafenibThe serum concentration of Sorafenib can be increased when it is combined with Chlorpropamide.Approved, Investigational
SotalolSotalol may increase the hypoglycemic activities of Chlorpropamide.Approved
SparfloxacinThe serum concentration of Sparfloxacin can be increased when it is combined with Chlorpropamide.Approved
SphingosineThe serum concentration of Sphingosine can be increased when it is combined with Chlorpropamide.Experimental
StanozololStanozolol may increase the hypoglycemic activities of Chlorpropamide.Approved, Vet Approved
StiripentolThe metabolism of Chlorpropamide can be decreased when combined with Stiripentol.Approved
SulfadiazineThe metabolism of Chlorpropamide can be decreased when combined with Sulfadiazine.Approved, Vet Approved
SulfamethoxazoleChlorpropamide may increase the hypoglycemic activities of Sulfamethoxazole.Approved
SulfisoxazoleThe metabolism of Chlorpropamide can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulodexideSulodexide may increase the hypoglycemic activities of Chlorpropamide.Approved, Investigational
SunitinibChlorpropamide may increase the hypoglycemic activities of Sunitinib.Approved, Investigational
TacrolimusThe serum concentration of Tacrolimus can be increased when it is combined with Chlorpropamide.Approved, Investigational
TamoxifenThe serum concentration of Tamoxifen can be increased when it is combined with Chlorpropamide.Approved
Taurocholic AcidThe serum concentration of Taurocholic Acid can be increased when it is combined with Chlorpropamide.Experimental
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Chlorpropamide.Approved
TelaprevirThe serum concentration of Telaprevir can be increased when it is combined with Chlorpropamide.Withdrawn
TemafloxacinTemafloxacin may increase the hypoglycemic activities of Chlorpropamide.Withdrawn
TemsirolimusThe serum concentration of Temsirolimus can be increased when it is combined with Chlorpropamide.Approved
TestosteroneTestosterone may increase the hypoglycemic activities of Chlorpropamide.Approved, Investigational
TicagrelorThe serum concentration of Ticagrelor can be increased when it is combined with Chlorpropamide.Approved
TiclopidineThe metabolism of Chlorpropamide can be decreased when combined with Ticlopidine.Approved
TimololThe serum concentration of Timolol can be increased when it is combined with Chlorpropamide.Approved
TipranavirThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Tipranavir.Approved, Investigational
TolazamideChlorpropamide may increase the hypoglycemic activities of Tolazamide.Approved
TolbutamideThe metabolism of Chlorpropamide can be decreased when combined with Tolbutamide.Approved
ToloxatoneToloxatone may increase the hypoglycemic activities of Chlorpropamide.Approved
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Chlorpropamide.Approved
TopiramateThe metabolism of Chlorpropamide can be decreased when combined with Topiramate.Approved
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Chlorpropamide.Approved, Investigational
TorasemideThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Torasemide.Approved
ToremifeneThe serum concentration of Toremifene can be increased when it is combined with Chlorpropamide.Approved, Investigational
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypoglycemic activities of Chlorpropamide.Experimental
TranylcypromineTranylcypromine may increase the hypoglycemic activities of Chlorpropamide.Approved
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be increased when it is combined with Chlorpropamide.Approved
TriamcinoloneThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Triamcinolone.Approved, Vet Approved
TrichlormethiazideThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Trichlormethiazide.Approved, Vet Approved
TrimethoprimThe metabolism of Chlorpropamide can be decreased when combined with Trimethoprim.Approved, Vet Approved
TriptorelinThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Triptorelin.Approved, Vet Approved
TroglitazoneTroglitazone may increase the hypoglycemic activities of Chlorpropamide.Withdrawn
TrovafloxacinTrovafloxacin may increase the hypoglycemic activities of Chlorpropamide.Approved, Withdrawn
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Chlorpropamide.Approved
UmeclidiniumThe serum concentration of Umeclidinium can be increased when it is combined with Chlorpropamide.Approved
Valproic AcidThe metabolism of Chlorpropamide can be decreased when combined with Valproic Acid.Approved, Investigational
ValsartanThe metabolism of Chlorpropamide can be decreased when combined with Valsartan.Approved, Investigational
VecuroniumThe serum concentration of Vecuronium can be increased when it is combined with Chlorpropamide.Approved
VenetoclaxThe serum concentration of Venetoclax can be increased when it is combined with Chlorpropamide.Approved
VenlafaxineThe serum concentration of Venlafaxine can be increased when it is combined with Chlorpropamide.Approved
VerapamilThe serum concentration of Verapamil can be increased when it is combined with Chlorpropamide.Approved
VildagliptinVildagliptin may increase the hypoglycemic activities of Chlorpropamide.Approved, Investigational
VinblastineThe serum concentration of Vinblastine can be increased when it is combined with Chlorpropamide.Approved
VincristineThe serum concentration of Vincristine can be increased when it is combined with Chlorpropamide.Approved, Investigational
VismodegibThe serum concentration of Vismodegib can be increased when it is combined with Chlorpropamide.Approved
VogliboseVoglibose may increase the hypoglycemic activities of Chlorpropamide.Approved, Investigational
VoriconazoleThe serum concentration of Chlorpropamide can be increased when it is combined with Voriconazole.Approved, Investigational
VorinostatThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Vorinostat.Approved, Investigational
WarfarinChlorpropamide may increase the anticoagulant activities of Warfarin.Approved
ZafirlukastThe metabolism of Chlorpropamide can be decreased when combined with Zafirlukast.Approved, Investigational
ZidovudineThe serum concentration of Zidovudine can be increased when it is combined with Chlorpropamide.Approved
ZimelidineZimelidine may increase the hypoglycemic activities of Chlorpropamide.Withdrawn
ZiprasidoneThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Ziprasidone.Approved
Food Interactions
  • Avoid alcohol.
  • Food reduces the rate of absorption.
  • Take 30 minutes before meal.
References
Synthesis Reference

McLamore, W.M.; U S . Patent 3,349,124; October 24,1967; assigned to Chas. Pfizer Co., Inc.

General ReferencesNot Available
External Links
ATC CodesA10BB02 — Chlorpropamide
AHFS Codes
  • 68:20.20
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (35.8 KB)
Clinical Trials
Clinical Trials
PhaseStatusPurposeConditionsCount
2CompletedTreatmentImpaired Glucose Tolerance (IGT) / Type 2 Diabetes Mellitus1
Not AvailableCompletedNot AvailableType 2 Diabetes Mellitus3
Not AvailableCompletedScreeningDiabetes Insipidus / Diabetes Insipidus, Neurohypophyseal1
Pharmacoeconomics
Manufacturers
  • Barr laboratories inc
  • Clonmel healthcare ltd
  • Duramed pharmaceuticals inc sub barr laboratories inc
  • Halsey drug co inc
  • Ivax pharmaceuticals inc
  • Mylan pharmaceuticals inc
  • Par pharmaceutical inc
  • Pliva inc
  • Sandoz inc
  • Superpharm corp
  • Teva pharmaceuticals usa inc
  • Usl pharma inc
  • Watson laboratories inc
  • Pfizer laboratories div pfizer inc
Packagers
Dosage forms
FormRouteStrength
TabletOral100 mg
TabletOral250 mg
TabletOral100 mg/1
TabletOral250 mg/1
Prices
Unit descriptionCostUnit
Diabinese 250 mg tablet1.34USD tablet
Diabinese 100 mg tablet0.61USD tablet
Chlorpropamide 250 mg tablet0.46USD tablet
Chlorpropamide 100 mg tablet0.33USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point (°C)129.2-129.8McLamore, W.M.; U S . Patent 3,349,124; October 24,1967; assigned to Chas. Pfizer Co., Inc.
water solubility258 mg/L (at 37 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP2.27HANSCH,C ET AL. (1995)
logS-3.03ADME Research, USCD
pKa5.13LIPINSKI,CA ET AL. (1991)
Predicted Properties
PropertyValueSource
Water Solubility0.157 mg/mLALOGPS
logP2.15ALOGPS
logP1.94ChemAxon
logS-3.2ALOGPS
pKa (Strongest Acidic)4.33ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area75.27 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity65.43 m3·mol-1ChemAxon
Polarizability27.06 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9969
Blood Brain Barrier+0.8087
Caco-2 permeable-0.6198
P-glycoprotein substrateNon-substrate0.6087
P-glycoprotein inhibitor INon-inhibitor0.9009
P-glycoprotein inhibitor IINon-inhibitor0.9533
Renal organic cation transporterNon-inhibitor0.8747
CYP450 2C9 substrateSubstrate0.5553
CYP450 2D6 substrateNon-substrate0.8806
CYP450 3A4 substrateNon-substrate0.7042
CYP450 1A2 substrateNon-inhibitor0.9044
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9026
CYP450 3A4 inhibitorNon-inhibitor0.9592
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.6454
Ames testNon AMES toxic0.9133
CarcinogenicityNon-carcinogens0.7685
BiodegradationNot ready biodegradable0.9206
Rat acute toxicity2.1413 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9072
hERG inhibition (predictor II)Non-inhibitor0.9306
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted GC-MSPredicted GC-MS Spectrum - GC-MSNot Available
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-qTof , PositiveNot Available
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-qTof , PositiveNot Available
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-qTof , PositiveNot Available
LC-MS/MSLC-MS/MS Spectrum - , positivesplash10-0002-0093000000-fa4d8bff1a5b0d68d8eaView in MoNA
LC-MS/MSLC-MS/MS Spectrum - , positivesplash10-006x-0910000000-a09d8795a568a12a0da3View in MoNA
LC-MS/MSLC-MS/MS Spectrum - , positivesplash10-03dr-2910000000-7ee6a1f4754e3058ddb6View in MoNA
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of chemical entities known as benzenesulfonamides. These are organic compounds containing a sulfonamide group that is S-linked to a benzene ring.
KingdomChemical entities
Super ClassOrganic compounds
ClassBenzenoids
Sub ClassBenzene and substituted derivatives
Direct ParentBenzenesulfonamides
Alternative ParentsBenzenesulfonyl compounds / Sulfonylureas / Chlorobenzenes / Aryl chlorides / Organosulfonic acids and derivatives / Aminosulfonyl compounds / Propargyl-type 1,3-dipolar organic compounds / Carboximidic acids and derivatives / Organopnictogen compounds / Organooxygen compounds
SubstituentsBenzenesulfonamide / Benzenesulfonyl group / Chlorobenzene / Halobenzene / Sulfonylurea / Aryl chloride / Aryl halide / Organic sulfonic acid or derivatives / Organosulfonic acid or derivatives / Sulfonyl
Molecular FrameworkAromatic homomonocyclic compounds
External Descriptorsmonochlorobenzenes, N-sulfonylurea (CHEBI:3650 )

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Sulfonylurea receptor activity
Specific Function:
Subunit of the beta-cell ATP-sensitive potassium channel (KATP). Regulator of ATP-sensitive K(+) channels and insulin release.
Gene Name:
ABCC8
Uniprot ID:
Q09428
Uniprot Name:
ATP-binding cassette sub-family C member 8
Molecular Weight:
176990.36 Da
References
  1. Mizuno CS, Chittiboyina AG, Kurtz TW, Pershadsingh HA, Avery MA: Type 2 diabetes and oral antihyperglycemic drugs. Curr Med Chem. 2008;15(1):61-74. [PubMed:18220763 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Uniprot Name:
Cytochrome P450 2C9
Molecular Weight:
55627.365 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:
CYP2C19
Uniprot ID:
P33261
Uniprot Name:
Cytochrome P450 2C19
Molecular Weight:
55930.545 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Prostaglandin-endoperoxide synthase activity
Specific Function:
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Involved in the constitutive production of prostanoids in particular in the stomach and platelets. In gastric epithelial cells, it is a key step in the generation of prostaglandins, such as prostaglandin E2 (PGE2), which plays an important role in cytoprotection. In platelets, it is involved in the gener...
Gene Name:
PTGS1
Uniprot ID:
P23219
Uniprot Name:
Prostaglandin G/H synthase 1
Molecular Weight:
68685.82 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Uniprot Name:
Multidrug resistance protein 1
Molecular Weight:
141477.255 Da
References
  1. Ibrahim S, Peggins J, Knapton A, Licht T, Aszalos A: Influence of antipsychotic, antiemetic, and Ca(2+) channel blocker drugs on the cellular accumulation of the anticancer drug daunorubicin: P-glycoprotein modulation. J Pharmacol Exp Ther. 2000 Dec;295(3):1276-83. [PubMed:11082465 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Proton-dependent oligopeptide secondary active transmembrane transporter activity
Specific Function:
Proton-coupled intake of oligopeptides of 2 to 4 amino acids with a preference for dipeptides. May constitute a major route for the absorption of protein digestion end-products.
Gene Name:
SLC15A1
Uniprot ID:
P46059
Uniprot Name:
Solute carrier family 15 member 1
Molecular Weight:
78805.265 Da
References
  1. Terada T, Sawada K, Saito H, Hashimoto Y, Inui K: Inhibitory effect of novel oral hypoglycemic agent nateglinide (AY4166) on peptide transporters PEPT1 and PEPT2. Eur J Pharmacol. 2000 Mar 24;392(1-2):11-7. [PubMed:10748266 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Peptide:proton symporter activity
Specific Function:
Proton-coupled intake of oligopeptides of 2 to 4 amino acids with a preference for dipeptides.
Gene Name:
SLC15A2
Uniprot ID:
Q16348
Uniprot Name:
Solute carrier family 15 member 2
Molecular Weight:
81782.77 Da
References
  1. Terada T, Sawada K, Saito H, Hashimoto Y, Inui K: Inhibitory effect of novel oral hypoglycemic agent nateglinide (AY4166) on peptide transporters PEPT1 and PEPT2. Eur J Pharmacol. 2000 Mar 24;392(1-2):11-7. [PubMed:10748266 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Involved in the renal elimination of endogenous and exogenous organic anions. Functions as organic anion exchanger when the uptake of one molecule of organic anion is coupled with an efflux of one molecule of endogenous dicarboxylic acid (glutarate, ketoglutarate, etc). Mediates the sodium-independent uptake of 2,3-dimercapto-1-propanesulfonic acid (DMPS) (By similarity). Mediates the sodium-in...
Gene Name:
SLC22A6
Uniprot ID:
Q4U2R8
Uniprot Name:
Solute carrier family 22 member 6
Molecular Weight:
61815.78 Da
References
  1. Uwai Y, Saito H, Hashimoto Y, Inui K: Inhibitory effect of anti-diabetic agents on rat organic anion transporter rOAT1. Eur J Pharmacol. 2000 Jun 16;398(2):193-7. [PubMed:10854830 ]
Drug created on June 13, 2005 07:24 / Updated on September 01, 2017 10:30